Actively Recruiting
Study of Partial Neuromuscular Blockade Using Cisatracurium to Support Safe Breathing in Adults with Moderate to Severe Acute Hypoxemic Respiratory Failure on Mechanical Ventilation or ECMO
Led by University Health Network, Toronto · Updated on 2026-01-06
23
Participants Needed
1
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new approach to managing breathing in patients with moderate to severe acute hypoxemic respiratory failure AHRF who require invasive mechanical ventilation. The study aims to assess the safety and feasibility of using partial neuromuscular blockade to allow safe spontaneous breathing while protecting the lungs. This approach may help avoid complications linked to full neuromuscular blockade commonly used in these patients. The study involves administering an infusion of the drug cisatracurium to maintain moderate inspiratory effort, measured by expiratory occlusion pressure Pocc between -5 and -15 cmH2O, after ensuring adequate sedation. The sedation and drug dosage will be adjusted to maintain these targets while monitoring respiratory comfort and muscle activity. The intervention lasts for 48 hours or until the patients hypoxemia improves to specified levels. Participants will be closely monitored during the intervention period with assessments including respiratory effort, sedation levels, hemodynamics, and safety measurements like train-of-four ratio. The main outcome is the rate of patients achieving and maintaining targeted Pocc over 48 hours. Researchers will also track serious adverse events and patient recall of paralysis after extubation. The total participation period aligns with the intervention and observation timeframe.
CONDITIONS
Brief Title
Partial Neuromuscular Blockade in Acute Hypoxemic Respiratory Failure
Research Team
G
Glauco M. Plens, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here